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Abstract
Background Gene-modifying trials offer hope for improvement in chronic paediatric disorders, but
they may also lead to disappointment and have an adverse emotional effect on families. This study
aimed to examine emotional impact on participants in a paediatric exon-skipping trial.
Methods Nineteen male children with Duchenne muscular dystrophy (DMD), and their parents,
taking part in a dose-ranging study of an i.v. administered morpholino splice-switching oligomer
(which can restore the reading frame in DMD and induce dystrophin expression) underwent a
psychosocial/psychiatric examination at trial entry. Emotional impact was assessed at trial
completion using questionnaires.
Results The mean child age was 8.9 years (SD 2.1); 13(68%) were attending mainstream school.
Most families were well adjusted psychosocially at trial entry. Post-trial median child emotional
impact scores were 5/10 (n = 18), but impact was rated as positive by 6/14 (42%), neutral/mixed by
5 (35%) and negative by 3 (21%). Median post-trial psychosocial/psychiatric change scores in
children and parents were minimal. Actual post-trial negative impact was statistically significantly
associated with higher expected impact at trial entry, at which time the families of the three
children displaying actual negative impact reported higher family stress levels in combination with
a variety of other psychosocial risks factors.
Conclusions In carefully selected families with low levels of psychosocial stress/distress at trial
entry, and with good support from paediatric research units (including psychiatric input when
required), genetic trials in progressive disorders such as DMD can have a predominantly positive or
neutral emotional impact. Nevertheless, negative impact is reported by a minority of families and
possible psychosocial predictors deserving further scrutiny have been identified.
Introduction
The recent advent of genetic therapies is starting to bring new
hope to children with progressive disorders such as Duchenne
muscular dystrophy (DMD). These therapies are, however, still
at early stages in clinical trials: the expected clinical implications
are minimal or uncertain, and there are a number of reasons
why they could have a de-stabilizing effect on the family’s
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adaptation to the illness. First, the trial will disrupt usual rou-
tines and bring into sharper focus the deteriorating condition in
the child, possibly re-awakening underlying concerns. High
levels of mental distress have been noted in mothers of children
with DMD at the stage when knee–ankle–foot orthoses are
introduced to prolong independent motility, which has been
attributed in part to having to confront the reality of the child’s
deterioration (Garralda et al. 2006). Second, trials may generate
unwarranted hope – as in ‘therapeutic misconception’ whereby
in spite of full informed consent patients can still overestimate
the beneficial effects of the therapeutic intervention and under-
estimate its adverse side effects (Kimmelman & Palmour 2005;
Henderson et al. 2006) – and this may lead to subsequent dis-
appointment and distress. Lastly, the trial will make demands
on the family in relation to time, travel and hospital contact: this
may prove especially stressful for families at the stage of adapt-
ing to deteriorating mobility in their child.
However, even though research ethics committees often
express concerns about protecting children they see as specially
‘vulnerable’ (Angell et al. 2010), little is known about the psy-
chological effect that taking part in research trials generally has
on children and their families/parents, nor on the specific effects
of participating in genetic trials.
A previous proof-of-concept genetic trial exploration in chil-
dren with DMD identified therapeutic misconceptions in 1/8
families and an emotional impact from the trial in 2/5 children,
both associated with high levels of psychosocial/psychiatric
stress at trial entry (Garralda et al. 2011).
The main aims of the present study were to explore the pos-
sible emotional impact on children with DMD and their parents
of taking part in an exon-skipping clinical trial to evaluate the
drug safety profile and to identify psychosocial/psychiatric pre-
dictors of emotional impact. It was hypothesized that a minor-
ity of children would experience an adverse emotional reaction,
and that this would be predicted by difficult psychosocial cir-
cumstances at trial entry.
Methods
Participants
Nineteen children with DMD and their families were recruited
into a phase II open-label, six-cohort dose escalation study of an
i.v. administered antisense oligomer (AVI-4658) which restores
the reading frame in amenable cases of DMD and may induce
dystrophin restoration. All 19 took part in the psychosocial
evaluation. The trial was conducted in two different children’s
hospitals and was approved by the relevant institutional ethics
committees. The main results have been reported elsewhere
(Cirak et al. 2011): this demonstrated the potential of AVI-4658
as a disease-modifying drug in the treatment of DMD, as it
induced skipping of exon 51 in all children, followed by the
appearance of dystrophin protein in those given the higher
doses. Dystrophin-associated proteins were also restored while
muscle inflammation was reduced; no drug-related serious
adverse events were recorded.
Procedure
For the trial – which lasted up to 38 weeks – informed consent
was obtained from families. Children were screened up to 12
weeks prior to the first dose of study drug; during the 12-week
treatment period they received weekly drug infusions, provided
urine and blood samples and underwent routine safety assess-
ments. Participants had three additional safety evaluations at
monthly intervals and a muscle biopsy (in two children under
general anaesthesia). Safety evaluations were further conducted
2 weeks after the last dose of the study was administered.
The psychosocial evaluation involved psychosocial/
psychiatric interviews with parents and children at the trial
screening phase conducted by psychiatrists/psychologist and
complemented by questionnaires; parents also completed ques-
tionnaires at trial completion to assess the trial’s emotional
impact and any changes in psychosocial/psychiatric status.
Measures
At trial entry information was obtained about socio-
demographic circumstances, previous and current child and
parent psychiatric adjustment, as well as on the practical and
emotional impact on parents and families of major past con-
cerns about the child’s illness (scored on an 11-point scale, with
10 representing the highest impact). Parent and child expecta-
tions from the trial were scored by the interviewer as ‘realistic’,
‘possibly unrealistic’ or ‘definitely unrealistic’ and in addition,
parents rated on an 11-point scale the expected emotional
impact of the trial on family members.
Serious concerns about the family’s ability to cope with the
trial procedures were regarded as exclusion criteria, but in the
event no families were excluded on this basis.
Family psychosocial and psychiatric risk
assessment questionnaires
To assess family psychosocial stressors and supports we used the
Parental Stress and Supports Questionnaire (PSSQ; Bailey &
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Garralda 1987). This is rated by parents in eight domains (occu-
pation, finances, housing, social relationships with extended
family and with friends, marriage, child with DMD and other
children at home) and provides information about the degree of
stress and support experienced at the time of assessment. Each
domain is rated according to the degree of stress/support expe-
rienced on a 4-point scale (2 indicating ‘marked’ and 3 ‘extreme’
levels of stress/support). A total score is derived by summing the
individual items (maximum score of 24 for stress and support
respectively).
Parents also completed the General Health Questionnaire
(GHQ-28; Goldberg 1978) about their own mental health. This
is a well-validated questionnaire assessing mental distress in
adults; the threshold score of5 indicates high psychiatric risk.
Child psychiatric risk assessment questionnaires
Parents completed the Strengths and Difficulties Questionnaire
(SDQ) to document psychiatric risk or emotional and behav-
ioural problems experienced by the child in the previous 6
months. The SDQ provides one total problems and five sub-
scale scores (emotional, conduct, hyperactivity, peer problems
and prosocial behaviour) as well as an impact score. Validated
cut-offs indicating risk for psychiatric disorder are available; a
total score of 17 indicates high risk for psychiatric disorder, a
score of 5 on the emotional scale indicates a risk for an emo-
tional disorder and an impact score of 2 is considered an
indication of a clinical problem.
Trial impact scores
As main outcome measure, at trial completion parents were
asked to indicate on an 11-point Likert scale the actual emo-
tional impact from participating in the trial on the child and
each parent (0 indicating none and 10 high impact). They also
indicated the nature of the impact, i.e. whether positive, nega-
tive or neutral, and they completed the same psychosocial and
psychiatric questionnaires as at trial entry to assess change in
psychiatric status.
Data analysis included frequency counts, correlation and
comparative data analysis. We used Wilcoxon signed-rank and
Mann–Whitney tests and one-tailed Spearman correlations as
appropriate.
Results
Both parents were interviewed in 12 (63%) cases. Demographic
details are given in Table 1. The mean child age was 8.9 years
(SD 2.1) and most children were at the late ambulatory stage in
the disease (they were able to walk with difficulty).
At trial entry psychosocial/psychiatric difficulty was present in a
minority of families (Table 1). High current psychosocial stress on
the PSSQ was reported by 15% and 11% of mothers were at risk of
mental distress on the GHQ; a past history of family depressive
disorder was noted by 16%. High risk for current psychiatric disor-
der in the child on the SDQ was found in one child. Expectations
about the trial were judged to be appropriate in all families and
mean expected emotional impact scores were low.
During the trial psychological concerns were raised with
regards to three children. One child was noted to be becoming
anxious and upset about the trial and its possible side effects
and was seen again by the child psychiatrist; the anxieties were
allayed at interview and the child entered and completed the
trial successfully. A second child had learning and behavioural
difficulties and there was concern about his ability to co-operate
with the trial infusions; this was discussed between the child
psychiatrist, parents and trial staff, and a satisfactory procedure
agreed. The third child was reluctant to have his final trial
biopsy following earlier difficulties with venupuncture; he was
re-assessed by the child psychiatrist and it was agreed not to
proceed with the biopsy.
At the end of the trial 18 parents reported actual trial impact
scores on the child, 17 on mothers and 13 on fathers (Fig. 1).
The nature of the impact was reported for 14 children, 12
mothers and 10 fathers. Actual impact scores were higher than
expected scores and correlations between them low for child
impact (r = 0.12; P = NS), but statistically significant for mother
(r = 0. 57; P = 0.009) and father scores (r = 0.56; P = 0.04).
There was generally good agreement between comments
made by the parents and the nature and degree of impact they
reported. Some inconsistency was noted in the scores of one
mother who rated the impact on the child as 5 and neutral, but
commented that he had been tired and worried about missing
school; she rated the impact on herself as 8 and as neutral but
described the trial as stressful and tiring for her.
Emotional impact of the trial on the child
Figure 1 shows that actual impact on the child was rated as
positive in nearly half the cases and as neutral in over a quarter.
Median impact scores for both positive and negative ratings
were comparable (8 and 7 out of 10 respectively), while the
median score for neutral ratings were lower (2/10). Positive
comments included statements that children enjoyed the
process and meeting people as well as other boys with DMD,
and that they were proud to take part in the trial and felt some
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good was being done. A parent noted that the child was a bit
scared at first but was fine once the trial started.
Negative comments included the hospital being a bit scary for
the child, stress regarding injections and blood samples, and
realizing a deterioration in the condition as the trial went on,
with depression that nothing positive had come out of it after
the considerable effort made.
The comparison of child SDQ psychiatric questionnaire
scores before and after the trial revealed few differences, median
change scores being zero for parentally rated child SDQ total
problems, conduct, hyperactivity, peer relationship and impact
scores. Only the change in the child’s SDQ emotional sub-scores
(positive median change of 1, or mean change of 0.56) indicated
an increase in symptoms. Nevertheless, these changes were
unrelated to the emotional impact scores.
Emotional impact of the trial on parents
Figure 1 shows that mothers reported the highest median actual
impact scores but, as with the children, this was mainly rated as
positive in nature. Comments reflected excitement at being part
of the trial, an ability to do something for a condition currently
without cure, seeing improvements in the child’s walking, and
also in everyday management. Negative impact was reported by
two mothers (who also gave the highest negative impact scores
for their children) and reflected the stress of spending 1 day a
week on the trial, tiredness, confusion, and having to remain
positive when the child found the process (such as injections)
difficult.
Fathers generally reported the lowest impact scores of all
three respondents per family, and their comments were very
similar to the mothers’. For the rest of the analysis therefore
only child and mothers’ results are considered.
Comparisons of the maternal psychosocial stress and mental
distress questionnaire scores before and after the trial revealed
few differences. Median change scores were zero for maternal
mental distress on the GHQ and median change in the total
psychosocial stress score small (-0.50). As with the children,
there were not associations between maternal psychiatric
change and trial impact scores.
Table 1. Sample characteristics and psychosocial factors at trial entry (n = 19)
Demographic data
Mean age 8.95 years (SD 2.1)
n (%)
Living with two biological parents 12 (63)
Father in external employment 16 (84)
Mother in external employment 11 (58)
White ethnicity (n = 18) 17 (94)
Attending mainstream school 13 (68)
Below average educational performance (n = 18) 4 (22)
Family history of depression 3 (16)
Mean (SD) Median (quartile) n (%)* (at risk)
Impact on family of past major illness concerns Practical 2.4 (3.2) 1 (0, 4) 4 (21)
Emotional 2.8 (3.7) 1 (0, 5) 5 (26)
Expected emotional impact from trial On child 2.1 (2.1) 1 (0, 4) 4 (21)
On mother 3.2 (2.8) 4 (1, 4) 3 (16)
Current psychosocial family stress total score (PSSQ) (n = 13) 6.5 (4.4) 6 (4, 9) 2 (15)
Current psychosocial family support total score (PSSQ) (n = 13) 13.3 (5.1) 11.5 (9, 7.25)
Satisfaction with support for child’s illness (n = 18) 6.9 (2.6) 7 (6, 9) 2 (11)
Current maternal distress (GHQ) (n = 17) 1.4 (3.3) 0 (0, 0.5) 2 (11)
Current paternal distress (GHQ) (n = 10) 0.1 (0.3) 0 (0, 0) 0
Child SDQ (parent-rated) Total score 8.8 (4.7) 10 (5, 12) 1 (5)
Impact score (n = 12) 0.6 (1.4) 0 (0, 0.75) 1 (8)
Emotional sub-score 1.8 (1.5) 1 (1, 3) 1 (5)
Peer relationship sub-score 1.6 (1.5) 2 (0, 2) 2 (11)
Prosocial sub-score 7.9 (1.8) 8 (7, 10) 2 (11)
Conduct sub-score 1.7 (1.5) 1 (0, 3) 3 (16)
Hyperactivity sub-score 3.7 (2.3) 4 (2, 6) 2 (11)
*The number of families at risk, i.e. scoring above/below mid-point on the PSSQ/impact/satisfaction scores, or above the cut-offs for psychiatric disorder on
GHQ & SDQ.
GHQ, General Health Questionnaire; PSSQ, Parental Stress and Supports Questionnaire; SDQ, Strengths and Difficulties Questionnaire.
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Associations with actual negative trial impact on the child
We considered whether the negative impact reported for three
of the children could have been predicted by any of the psycho-
social factors measured at trial entry. However, the only statis-
tical association was with the expected impact scores, which
were significantly higher among these children [median 5 (2, 6)
vs. 0.5 (0, 2.5); Mann–Whitney P = 0.031; mean 4.3 (SD 2.1) vs.
1.2 (SD 1.8)].
None of the children who had received psychiatric assistance
during the trial rated the impact negatively, nor was this explic-
itly linked by any of the parents to untoward physical effects of
the trial over and above the comments made about injections/
cannulation.
Since this was an exploratory study and the statistical power
to identify predictors of impact small, we examined whether
there were any obvious risks shared by the three families report-
ing an actual negative impact on the children. Table 2 shows
that these families had the highest total stress scores of all on the
PSSQ at trial entry. In addition, individual families scored
highly practical impact in the past from concerns about the
child’s illness, maternal mental distress and child emotional
symptoms; they included the only single-parent family, another
reporting a stressful parental situation and the family with the
second lowest level of satisfaction with the amount of support
received in managing their child’s illness. But it was the combi-
nation of problems in various areas simultaneously that
appeared relevant.
Discussion
In this dose-ranging exon-skipping trial in primary-school aged
children with DMD, an emotional impact from the trial was
reported by most families, more so than anticipated by them at
trial entry. Impact was mostly rated as positive in nature and
there were only minimal changes in family psychosocial and
psychiatric status over the course of the trial. Nevertheless, a
Expected and actual emotional trial impact median scores
(10=max impact)
Median
score
Median
score
No. of cases
Nature of actual emotional impact from trial
Median child actual emotional impact scores by
type of impact
8
6
4
2
0
6
5
4
3
2
1
0
8
7
6
5
4
3
2
1
0
Median impact
Positive Neutral Negative Mixed
Child
Mother
Father
Positive
Negative
Mixed
Neutral
Child Mother Father
Expected impact
Actual impact
Figure 1. Expected and actual trial emotional impact scores in children
and parents.
Table 2. Psychosocial stressors in the three families reporting negative
impact from the trial on the child
Family 1 Family 2 Family 3
Trial negative emotional impact score 9 7 4
Practical impact from child illness in the
past
- + -
Expected trial impact + + -
PSSQ total stress + + (-)* +
Maternal GHQ total - - +
Parental marital stress - + -
Child SDQ emotional score + - -
Satisfaction with support with illness - +† -
Single-parent family - - +
*Different ratings by mother/father.
†Second lowest rating of whole group.
+ = highest/single adverse scores in the whole group.
GHQ, General Health Questionnaire; PSSQ, Parental Social Stress and Supports
Questionnaire; SDQ, Strengths and Difficulties Questionnaire.
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negative trial impact was reported for a minority of children
and mothers. Preliminary exploration indicates that a combi-
nation of different types of psychosocial stressors may predict
the development of negative emotional reactions and is worth
exploring further.
It is important to note that families had volunteered for this
study and a self-selection process is likely to have taken place,
appropriately for a trial making considerable practical and emo-
tional demands on families. Most were well adjusted psychoso-
cially and psychiatrically at trial entry. The results might have
been different if less psychosocially robust families had been
sampled.
All the families expressed adequate overall knowledge and
expectations about the trial, making therapeutic misconcep-
tions an unlikely source of negative emotional impact (Kimmel-
man & Palmour 2005; Henderson et al. 2006). This appears at
variance with the report by Chappuy and colleagues (2010) in
which 19% of parents signing consent forms for a trial in child-
hood leukaemia had not even realized that their child had been
included in a research protocol, and half the parents could not
explain the aim of the clinical trial nor the potential benefit of
inclusion for their child. It is possible – following identification
of distressing misconceptions in one family in a prior proof-
of-concept study (Garralda et al. 2011) – that the explanatory
emphasis of our research team was greater. Alternatively, better
understanding of the trial might be easier to achieve in families
who already have a good deal of knowledge about a progressive
disease such as in DMD or with small trial samples such as ours.
The fact that emotional impact from the trial was mostly
rated as ‘positive’ or ‘neutral’ and that the trial did not affect the
child or parents’ psychiatric status indicates that in adequately
selected families, and when good research support is provided,
children and their parents may actually feel a benefit. This infor-
mation should be helpful to ethics committees when consider-
ing clinical research with children (Angell et al. 2010). It is
worth noting that the support available to the research units in
the current study included psychiatric input, and it is interesting
that none of the children who received psychiatric assistance
during the trial rated its impact as negative (two scored it as
positive and one as neutral).
However, a minority of families reported experiencing a
negative impact citing distress over the physical procedures and
disappointment about their child’s deterioration as the cause.
The exploratory nature of this study does not allow a statistical
exploration of possible predictors of impact; nevertheless, there
are indications that a combination of pre-trial risk factors with
expectations of an emotional impact from the trial and high
levels of psychosocial stress at the time of entering the study
may be relevant. Psychosocial screening incorporating these
risks can be easily included at the trial assessment stage. It would
seem appropriate to further explore their relevance for the like-
lihood that children with progressive and other chronic disor-
ders and their families experience a negative emotional impact
from clinical trials.
Key messages
• In carefully selected families with low levels of psychoso-
cial stress and mental distress, well prepared and sup-
ported by paediatric research units (including psychiatric
input when thought to be required), genetic trials in pro-
gressive disorders such as DMD are most likely to have a
positive or neutral impact and lead to little change in the
psychiatric status of the child or parent.
• A negative impact is, however, reported by a minority of
families, connected with disappointment and difficulty
with the trial process.
• It would be helpful to further explore possible psychoso-
cial predictors of negative emotional impacts from paedi-
atric trials.
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